Pharmaceutical giant Bayer will support development of CureVac’s mRNA COVID-19 vaccine candidate across numerous areas: helping facilitate the global supply of several hundred million doses.
Akston Biosciences has announced a strategic partnership with LakePharma to manufacture commercial quantities of its COVID-19 vaccine candidate, as the room temperature stable vaccine gears up to begin Phase 1/2 clinical trials this month.
A new study suggests that CAR T-cells, which are already used to treat certain blood cancers, may also be successful against solid tumors if combined with other immunotherapeutic approaches.
People who have been infected with SARS-CoV-2 retain immune memory to protect against reinfection for 'at least eight months', according to Australian scientists. "This research is the strongest evidence for the likelihood that vaccines...
More than 360,000 people have signed up to the UK’s registry of people interested in participating in vaccine trials: the world’s first database of its kind. The UK is also exploring other measures – such as human challenge trials - to boost clinical...
BioNTech's CEO says it is highly likely that the Pfizer/BioNTech vaccine will be able to deal with the new variant that has emerged in the UK. And a new vaccine could be developed within six weeks if needed.
Valneva has started a Phase 1/2 trial of its COVID-19 vaccine: eying up potential regulatory approval in the fourth quarter of 2021. It champions a ‘tried and tested’ approach with its inactivated candidate.
The US has started COVID-19 vaccinations this morning: after the Pfizer/BioNTech vaccine was granted Emergency Use Authorization (EUA) by the FDA on Friday.
US headquartered company, Orgenesis, and South Korea-based, Cure Therapeutics, have signed a JV deal to advance the development, regulatory approval, and commercialization of point of care production for both companies’ cell and gene therapies and immunotherapies....
